A Phase 2 interventional study of imatinib mesylate in Philadelphia Chromosome Positive CML, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing imatinib in Blast Crisis — 1 open to participants now, 1 under way, none of them phase 3. imatinib · Blast Crisis.
Among the 15 studies testing imatinib in Blast Crisis, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 1999, is one of 7 in phase 2, and was the 7th registered.
361 studies on the registry are indexed under Blast Crisis; 16 are open to participants now.
Browse Blast Crisis studies →1 of the 15 studies testing imatinib in Blast Crisis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 14 Blast Crisis studies recruiting now, 9 (64%) set no upper age limit and 2 (14%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 36 across 264 interventional studies indexed under Blast Crisis.
Median enrollment 48 across the 10 interventional studies. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Blast Crisis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing imatinib in Blast Crisis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.
361 studies on the registry are indexed under Blast Crisis; 16 are open to participants now.
This study's enrollment of 260 is above the median of 36 across 264 interventional studies indexed under Blast Crisis.
Browse Blast Crisis studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Blast Crisis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.
Drug: imatinib mesylate
Also known as: Gleevec/Glivec
Overall Survival
Overall survival was defined as the number of events of death, expressed as a percentage, from the start of treatment to death, due to any reason.
Time frame: From first dose until death of the patient, up to 14 years.
Overall Survival (by Month)
Overall survival was defined as the time between start of treatment and death due to any reason. Overall survival for the participants was calculated by Kaplan-Meier estimates per month. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up.
Time frame: From first dose until death of the patient, up to 14 years.
The overall study was conducted at 28 investigative sites in 6 countries from 26 July 1999 to 22 April 2013. A total of 260 participants were enrolled in the core Study CSTI57A0102, of which 21 participants completed the treatment and were enrolled in the extension Study CSTI571A0102E1. 13 participants discontinued from the extension Study CSTI571A0102E1, and 8 of them were enrolled in the extension Study CSTI571A0102E2.
| Milestone | Imatinib Mesylate (STI571) |
|---|---|
| Started | 260 |
| Completed | 21 |
| Not completed | 239 |
| Withdrew: Death | 27 |
| Withdrew: Unsatisfactory therapeutic effect | 163 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Administrative problems | 1 |
| Withdrew: Adverse event, non-fatal | 21 |
| Withdrew: Consent withdrawn by subject | 6 |
| Withdrew: No longer required drug (bmt) | 14 |
| Withdrew: Abnormal laboratory values | 2 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | Imatinib Mesylate (STI571) |
|---|---|
| Started | 8 |
| Completed | 1 |
| Not completed | 7 |
| Withdrew: Other | 7 |
Overall survival was defined as the number of events of death, expressed as a percentage, from the start of treatment to death, due to any reason.
| percentage of participants | Imatinib Mesylate (STI571) |
|---|---|
| Overall Survival | 89.2 |
Overall survival was defined as the time between start of treatment and death due to any reason. Overall survival for the participants was calculated by Kaplan-Meier estimates per month. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up.
| percentage of participants | Imatinib Mesylate (STI571) |
|---|---|
| 12 Months | 32.7 (27.0 to 38.5) |
| 24 Months | 18.7 (14.2 to 23.8) |
| 36 Months | 15.4 (11.2 to 20.2) |
| 48 Months | 14.5 (10.4 to 19.2) |
| 60 Months | 9.1 (5.7 to 13.4) |
| 72 Months | 8.4 (5.2 to 12.7) |
| 84 Months | 7.5 (4.3 to 11.8) |
| 96 Months | 7.5 (4.3 to 11.8) |
| 108 Months | 7.5 (4.3 to 11.8) |
| 120 Months | 6.6 (3.5 to 11.0) |
| 132 Months | 5.5 (2.6 to 10.0) |
| 144 Months | 5.5 (2.6 to 10.0) |
| 156 Months | 5.5 (2.6 to 10.0) |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV) up to 14 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib Mesylate (STI571) | — | 0/260 (0%) | 0/260 (0%) |
The Intent-to-treat (ITT) population included all participants who enrolled in the study.
| Age, Continuous(years) | Imatinib Mesylate (STI571) |
|---|---|
| Median | 56 (19 to 81) |
| Sex: Female, Male(Participants) | Imatinib Mesylate (STI571) |
|---|---|
| Female | 124 |
| Male | 136 |
Ran from Jul 1999 to primary completion in Apr 2013, 165 months.
Results were first posted in Jun 2021, 8 years 2 months after primary completion.
Of 25 phase 2 interventional studies under Blast Crisis, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 165. This study's 165 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib